Anbio Biotechnology is venturing into the European domain with its premier product, the AF-100 C, an avant-garde compact fluorescent immunoassay analyser poised to redefine point-of-care diagnostics. Equipped with upwards of 70 assays, the AF-100 C is poised to bolster the capabilities of EU healthcare providers, thus enhancing patient treatment and prognostic accuracy.
In an ambitious effort to expand its footprint within the European Union, Anbio Biotechnology (Anbio), a leading entity in the field of in vitro diagnostics worldwide, proudly announces the launch of its comprehensive “Point of Care” product lineup in the EU. This landmark occasion signals Anbio’s venture into new collaborative territories with EU distributors and medical practitioners, underscoring the firm’s dedication to providing the EU market with advanced diagnostic options.
Known for its legacy of innovation and excellence, Anbio has transcended its image as a mere provider of Covid testing kits to emerge as a multifaceted creator and innovator of a wide spectrum of diagnostic tools. “Our mission is to revolutionize diagnostics by offering tailored and accessible solutions, including laboratory, wellness, at-home, and point-of-care diagnostics. We are committed to affordability and continuous innovation in life sciences that serve to advance human heath,” Michael Lau, Anbio’s Chief Executive, elucidated.
Revolutionary Analyzer Delivers Access to Key Over 70 Diagnostics
The promotion of Anbio’s offerings in the EU is spearheaded by the AF-100 C analyzer, a groundbreaking, portable, rechargeable compact fluorescent Immunoassay (FIA) analyzer of single-channel design. This formidable device, along with its over 70 CE-approved assays for a myriad of analytes such as inflammation indicators, diabetes, cancer markers, hormones, enzymes, and infectious diseases, is anticipated to significantly alter the EU’s clinical diagnostics scene.
“The Anbio AF-100 C is a game-changer for clinical diagnostics, supplying healthcare providers with a cost-effective, comprehensive, and reliable solution for rapid point-of-care testing,” Lau asserted. The AF-100 C’s compact form belies its high throughput capability, making it an ideal choice for varied clinical environments, from private healthcare settings to emergency departments. Its straightforward interface and long-lasting battery, supporting continuous operation for up to 8 hours, ensure that medical professionals can provide enhanced patient care with utmost efficiency and precision.
Swift and Accurate Diagnostics Foster Improved Healthcare Outcomes
The extensive FIA line from Anbio, capable of producing quick results in just 3 to 15 minutes, signifies a breakthrough in diagnostic technology. Featuring reagents that utilise RFID chip technology for enhanced accuracy and capable of storage at room temperature for two years, Anbio is set to meet the pressing needs of the European healthcare landscape.
With its establishment in the EU market, Anbio Biotechnology invites distributors and medical professionals to explore its pioneering diagnostic offerings. Dedicated to enhancing patient care through cost-effective, precise, and dependable diagnostics, Anbio is keen to collaborate with healthcare practitioners across the EU.
